Vitamin D receptor gene polymorphism and hepatocellular carcinoma in chronic hepatitis C patients

Hala Mosaad1, Emad A. Emam2, Emad F. Hamed2, Ezzat A. El Demerdash2 and Samia Hussein1*

Abstract
Background: Hepatocellular carcinoma (HCC) is a prevalent malignancy worldwide. Vitamin D receptor (VDR) gene polymorphisms were linked to different cancers. This study was carried out to assess the possible relation between VDR gene polymorphism and the occurrence of HCC in chronic hepatitis C patients. This study included 102 subjects classified into three groups. Group A included 34 healthy subjects as control. Group B included 34 chronic hepatitis C patients with HCC. Group C included 34 chronic hepatitis C patients without HCC. Estimation of Apa-1 VDR gene polymorphism was performed by restriction fragment length polymorphism-Polymerase chain reaction (RFLP-PCR).

Results: In HCC group, C allele was more frequent than A allele (80.88% and 19.12%), respectively. In chronic hepatitis group, C allele was more frequent than A allele (64.71% and 35.29%), respectively. In control group, A allele was more frequent than C allele (73.53% and 26.47%), respectively. Genotype CC + CA was dominant in HCC group (91.18%) and chronic hepatitis group (79.41%). In the control group, the dominant genotype was AA (58.82%). Moreover, there was a significant relation between Apa-1 VDR genotype CC and tumor size.

Conclusions: There is an association between VDR Apa-1 polymorphism and the occurrence of HCC in chronic hepatitis C patients.

Keywords: Vitamin D receptor gene polymorphism, Hepatocellular carcinoma, Chronic hepatitis C

Background
Hepatitis C virus (HCV) infection is a common health problem worldwide. Chronic HCV commonly proceeds to cirrhosis which may predispose to hepatocellular carcinoma (HCC). Hepatocarcinogenesis is affected by environmental and genetic features [1].

Risk factors for HCC include alcohol use, viral hepatitis, and metabolic diseases. Host genetics may play an important role. Improving our recognition of molecular factors may help us in early detection, stratification, individual treatment, and predicting the prognosis [2].

The importance of vitamin D has widened, from being only involved in bone metabolism to a broad scope of other physiological and pathological processes. It has an effect on immunity, intellectual and fetal development, insulin secretion, cancer, cell proliferation, and differentiation, and the cardiovascular system via the vitamin D receptor (VDR) which is a nuclear receptor. Vitamin D binds to its receptor to form a complex that enters the nucleus and binds to DNA regulating gene expression [3].

The VDR gene is located in chromosome 12q and has multiple allelic variants. Some of these variants may cause changes in the VDR function and may lead to immune-mediated disorders and cancer development. The most common of these variants are single nucleotide polymorphisms (SNPs). Four polymorphisms, Fok1, Bsm1, APa1, and Taq1, are being most investigated [4].
Several studies were performed and proved the association between VDR gene polymorphism and different types of cancer as cancer breast, prostate, bladder, and kidney. In our study, we clarified the effect of VDR gene polymorphism Apa1 in the occurrence of HCC among chronic hepatitis C patients.

**Methods**

This is a case-control study, and it was conducted in the Medical Biochemistry & Molecular Biology and Internal medicine Departments, Faculty of Medicine, Zagazig University, Egypt. Our study included 102 subjects classified into three groups. Group A comprised of 34 healthy subjects as control. Group B comprised of 34 chronic hepatitis C patients with HCC. Group C comprised of 34 chronic hepatitis C patients without HCC. Written informed consents from the participants were obtained before being involved in the study.

The patients participated in the study were chronic hepatitis C infection diagnosed by HCV-Ab and quantitative real-time polymerase chain reaction (PCR) and HCC was diagnosed by a triphasic CT scan. Patients excluded from the study were those with chronic hepatitis B infection, patients with other chronic liver diseases, patients having any other malignancy and patients who had diabetes mellitus, chronic renal failure or bone disorders.

All the participants were completely evaluated by complete history, examination, and full investigations in the form of laboratory studies as complete blood count (CBC) and complete renal and liver functions. DNA extraction was performed from whole blood using GeneJET whole Blood Genomic DNA Extraction Mini Kit (Molecular Biology, Thermo Fisher Scientific, USA). DNA amplification product. The mixture was incubated at 65 °C for 5 min. The reaction mixture was loaded directly and electrophoresed on 2% agarose gel containing ethidium bromide and visualized under ultraviolet illumination. PCR products with C at the polymorphic site were digested into two fragments, 531 and 214 bp, where those with A were not because of the absence of Apa-I enzyme restriction site. Samples yielding 531 bp and 214 bp fragments were scored as C/C, those with single 745 bp fragment as A/A, and 745-bp, 531-bp, and 214-bp fragments as A/C. The amount of size marker to load on the gel is 10 μl per lane and the result was photographed (Fig. 1).

**Statistical analysis**

Data were checked, entered, and analyzed by using (SPSS version 17 for windows, SPSS Inc., Chicago, IL, USA) and Medical 13 for windows (MedCalc Software bvba, Ostend, Belgium). Data were expressed as mean ± SD for quantitative variables or number and percentage for qualitative variables. Chi-squared (χ²), t test, and analysis of variance (ANOVA) tests were performed. Unpaired Student’s t test was used to compare between two groups in quantitative data.

**Results**

In our study, there were significant differences between the three groups regarding direct bilirubin, total bilirubin, serum alanine aminotransferase (ALT), serum aspartate aminotransferase (AST), serum albumin, serum alkaline phosphatase (ALP), serum AFP, serum creatinine, serum urea, platelet count, INR, and PT. But, there were no significant differences between the three studied groups regarding hemoglobin and body mass index (BMI) (Table 1).

According to genotypes distribution, in control group, CC genotype represents (11.76%), CA genotype (29.41%), and AA genotype (58.82%). In HCC group, CC genotype represents (70.59%), CA genotype (20.59%), and AA genotype (8.82%). Chronic hepatitis C group represents CC genotype (50%), CA genotype (29.41%), and AA genotype (20.59%). There was a significant difference between the groups regarding genotype distribution (P < 0.001) (Table 2).

According to allele frequency, the control group shows that A allele more frequent than the C allele (73.53%, 26.47%), respectively. In the HCC group, the C allele was more frequent than A allele (80.88%, 19.12%), respectively. In the chronic hepatitis C group, the C allele was more frequent than A allele (64.71%, 35.29%) respectively. There was a significant difference between the groups regarding allele frequency (Table 3).

Our study showed a significant relationship between VDR genotypes in HCC and both AFP (P = 0.02) and
tumor size ($P = 0.008$). There was a significant relationship between genotype CC and tumor size (Table 4).

**Discussion**

HCC is resistant to radiotherapy and chemotherapy, and long-term survival of patients occurred only with small asymptomatic HCC [5]. Early detection of HCC is helpful as it improves the prognosis [6]. And, it allows using several modalities as resection, radiofrequency ablation, and transplantation. These modalities improve the outcome in these patients [7].

It is important to recognize HCV-infected patients who are at a higher risk of developing HCC [8]. The difference in the incidences of HCC among different

### Table 1: Different biochemical data in the studied groups

|                        | Group A Control ($n = 34$) | Group B HCC ($n = 34$) | Group C chronic hepatitis ($n = 34$) | $P$ value |
|------------------------|----------------------------|------------------------|-------------------------------------|-----------|
| **Age**                | 49.3 ± 6.5                 | 53.8 ± 8.3$^a$         | 50.9 ± 6.9                          | 0.06$^*$  |
| **Gender (M/F)**       | 16/18                      | 23/11                  | 17/17                               | 0.182     |
| **BMI (kg/m$^2$)**     | 23.09 ± 0.45               | 23.19 ± 0.47           | 23.16 ± 0.49                        | 0.668     |
| **Total bilirubin (mg/dl)** | 0.85 ± 0.17               | 2.32 ± 1.33$^a$        | 1.87 ± 1.14$^b$                     | 0.005$^*$ |
| **Direct bilirubin (mg/dl)** | 0.39 ± 0.11               | 0.81 ± 0.58$^a$        | 0.97 ± 0.67$^b$                     | 0.032$^*$ |
| **ALT (IU/L)**         | 25 ± 3.55                  | 97.79 ± 25.32$^a$      | 91.41 ± 60.27$^b$                   | < 0.001$^{**}$ |
| **AST (IU/L)**         | 22.67 ± 4.28               | 77.71 ± 21.53$^a$      | 93.94 ± 85.15$^b$                   | < 0.001$^{**}$ |
| **Albumin (g/dl)**     | 4.22 ± 0.44                | 2.82 ± 0.71$^a$        | 3.06 ± 0.47$^b$                     | < 0.001$^{**}$ |
| **ALP (IU/L)**         | 64.35 ± 11.39              | 108.97 ± 37.7$^a$      | 112.38 ± 57.31$^b$                  | < 0.001$^{**}$ |
| **AFP (ng/mL)**        | 6.45 ± 1.63                | 3599.09 ± 4450.75$^a$  | 26.13 ± 23.87$^c$                   | < 0.001$^{**}$ |
| **Creatinine (mg/dL)** | 0.87 ± 0.12                | 1.04 ± 0.27$^a$        | 0.94 ± 0.19                         | 0.004$^*$ |
| **Urea (mg/dl)**       | 33.85 ± 3.74               | 31.59 ± 3.89$^a$       | 33.15 ± 2.87                        | 0.029$^*$ |
| **Hemoglobin (g/dL)**  | 12.71 ± 0.76               | 12.28 ± 1.61$^a$       | 12.03 ± 1.61$^b$                    | 0.125     |
| **Platelets count ($\times 10^3$ mm$^3$)** | 222 ± 49.14               | 134.97 ± 7.13$^a$      | 130.77 ± 73.72$^b$                  | < 0.001$^{**}$ |
| **INR**                | 1.02 ± 0.04                | 1.38 ± 0.39$^a$        | 1.49 ± 0.43$^b$                     | < 0.001$^{**}$ |
| **PT (s)**             | 12.27 ± 0.46               | 16.68 ± 4.91$^a$       | 17.89 ± 5.17$^b$                    | < 0.001$^{**}$ |

$^aP < 0.05$ is significant

$^bP < 0.001$ is highly significant

$^c$Significant difference between group A (control) and B (HCC)

$^d$Significant difference between group A (control) and C (chronic hepatitis)

$^e$Significant difference between group B (HCC) and C (chronic hepatitis)
populations may be explained by genetic background [9]. Besides, multiple susceptible genetic loci of HCC were also recognized and validated [10]. Thus, the study of genetics can be added to the tools of risk prediction, allowing better stratification and personalized assessment of optimal long-term management, thereby increasing the efficacy of surveillance programs [2].

The mechanism of development of HCC among chronic hepatitis C patients, including host- and viral-related factors, is still unknown. The differences in the prevalence and the strong gender distribution in HCC are due to differences in the exposure to the causative agents as well as genetic factors, particularly gene polymorphisms of inflammatory cytokines and growth factor ligands and receptors [11].

Vitamin D is not only involved in bone metabolism as a hormone but it also has immunomodulatory, anti-inflammatory, and antifibrotic properties. It also plays an important role in the regulation of cell proliferation, differentiation, and carcinogenesis via VDR [12]. VDR is a member of the nuclear receptor superfamily of ligand-inducible transcription factors, which are involved in many physiological processes, including cell growth and differentiation, embryonic development, and metabolic homeostasis [13]. VDR performs heterodimerization with auxiliary proteins for effective DNA interaction as the retinoid-X receptors (RXRs). Vitamin D response elements have been recognized in many genes responsible for cellular growth, differentiation, apoptosis, invasion, and metastasis of tumor cells as cell cycle regulators. Therefore, it can be assumed that VDR-mediated signaling pathways and VDR gene polymorphisms are related to carcinogenesis. Furthermore, VDR gene variants can modulate vitamin D effect without affecting serum vitamin D levels [14].

VDR polymorphisms have been studied in chronic liver diseases [15]. Yao et al. (2013) and Hoan et al. (2019) found that VDR polymorphism was a risk predictor and a prognostic molecular marker of HCC in patients with chronic hepatitis B [3, 16].

Polymorphisms are defined as variations in DNA sequence which occur in at least 1% of a certain population and have real biological effects. They have been studied with the aim of explaining association with the risk for common diseases [17]. According to Shastry (2002) and Li et al. (2001), humans have a huge number of polymorphisms that lead to different cellular effects due to different mechanisms such as transcription level modification, posttranscriptional, or posttranslational activity or changes in the tertiary structure of the gene product [17, 18]. Bai et al. (2012) stated that several SNPs have been described in the VDR gene, and some polymorphisms are associated with tumor occurrence in the breast, prostate, skin, colon-rectum, bladder, and kidney [19]. The most common allelic variants studied included a start codon polymorphism Fok1 (T/C) in exon II, Bsm1 (A/G), and APa1 (C/A) polymorphisms in the intron between exon VII and IX and a Taq1 (T/C) variant in exon IX [20]. The Apa-I is a silent SNP. No replacement of the amino acid occurs in the protein. However, it affects mRNA stability [21].

In this study, there was no statistically significant difference between the three studied groups regarding

| Table 2 | Comparison between the three studied groups according genotypes distribution |
|---------|-------------------------------------------------|
| Genotype | Group A | Group B | Group C |
|         | Control | HCC     | chronic hepatitis |
|         | (n = 34) | (n = 34) | (n = 34) |
| N | % | N | % | N | % |
| AA | 20 | 58.82 | 3 | 8.82 | 7 | 20.59 |
| CA | 10 | 29.41 | 7 | 20.59 | 10 | 29.41 |
| CC | 4 | 11.76 | 24 | 70.59 | 17 | 50.59 |

**P value < 0.001 (highly significant)**

| Table 3 | Comparison between the three studied groups according to allele frequency |
|---------|-------------------------------------------------|
| Genotype | Group A | Group B | Group C |
|         | Control | HCC     | chronic hepatitis |
|         | (n = 34) | (n = 34) | (n = 34) |
| N | % | N | % | N | % |
| A allele | 50 | 73.53 | 13 | 19.2 | 24 | 35.29 |
| C allele | 18 | 26.47 | 55 | 80.88 | 44 | 64.71 |

**P value < 0.001 (highly significant)**
sex distribution. There was a significant difference between HCC and control regarding age but not significantly higher than chronic hepatitis patients. These results were similar to those found by Barooah et al. (2019) [22]. In contrary to our results, Yang and Roberts (2010) reported that the risk of HCC is 2–7 times higher in men than in women, although this ratio varies across the world. Their explanation for this might be due to higher rates of environmental exposure to liver carcinogens (such as smoking or alcohol) and hepatitis virus infections. Also, estrogen might suppress interleukin IL-6 mediated inflammation in women, reducing both liver injury and compensatory proliferation. Moreover, testosterone effects could increase androgen receptor signaling in men, promoting liver cell proliferation [23]. Hammad et al. (2013) reported that HCC is significantly higher in men than women (77.7 and 22.3%, respectively) [24].

In our study, there were significant differences between the three groups regarding direct bilirubin, total bilirubin, serum ALT, serum AST, serum albumin, and AFP. These differences were consistent with previous studies.[22,24]

### Table 4: Relation between Apa-1 vitamin D receptor genotypes and different parameters in the hepatocellular carcinoma (HCC) group

| Group B (HCC) | Genotype | ANOVA | F  | P     |
|--------------|----------|-------|----|-------|
|              |          |       |    |       |
| Age (years)  | Range    | Mean ± SD |   |       |
|              | 44–66    | 54.000 ± 11.136 | 0.339 | 0.715 |
|              | 39–60    | 51.429 ± 7.161   | 0.523 | 0.598 |
|              | 33–68    | 51.429 ± 7.161   | 0.523 | 0.598 |
| T. bilirubin (mg/dl) | Range | Mean ± SD |   |       |
|              | 0.9–3    | 1.11–4.6   | 0.588 | 0.221 |
|              | 1.723 ± 1.121 | 2.456 ± 1.685 | 0.588 | 0.221 |
| D. bilirubin (mg/dl) | Range | Mean ± SD |   |       |
|              | 0.35–0.61 | 0.836 ± 0.299 | 0.787 | 0.264 |
|              | 0.520 ± 0.147 | 0.836 ± 0.299 | 0.787 | 0.264 |
| ALT (IU/L)   | Range | Mean ± SD |   |       |
|              | 77–133   | 65–180  | 68–134 | 0.125 | 0.883 |
|              | 98.667 ± 30.072 | 102.000 ± 39.770 | 96.458 ± 20.532 | 0.125 | 0.883 |
| AST (IU/L)   | Range | Mean ± SD |   |       |
|              | 49–112   | 62–116  | 53–119 | 0.117 | 0.890 |
|              | 104.000 ± 15.620 | 121.714 ± 24.074 | 105.875 ± 42.470 | 0.117 | 0.890 |
| S. albumin (g/dl) | Range | Mean ± SD |   |       |
|              | 2.3–3.8  | 1.8–3.2  | 1.5–3.9 | 1.598 | 0.218 |
|              | 3.033 ± 0.751 | 2.400 ± 0.432 | 2.908 ± 0.748 | 1.598 | 0.218 |
| ALP (IU/L)   | Range | Mean ± SD |   |       |
|              | 94–122   | 80–156  | 59–240 | 0.491 | 0.616 |
|              | 104.000 ± 15.620 | 121.714 ± 24.074 | 105.875 ± 42.470 | 0.491 | 0.616 |
| S. Creatinine (mg/dl) | Range | Mean ± SD |   |       |
|              | 0.65–1.3 | 0.65–1.8  | 0.75–1.42 | 1.625 | 0.213 |
|              | 0.950 ± 0.328 | 1.199 ± 0.385 | 1.004 ± 0.219 | 1.625 | 0.213 |
| AFP (ng/mL)  | Range | Mean ± SD |   |       |
|              | 70–430   | 86–1214 | 430–20834 | 4.455 | 0.020^* |
|              | 256.667 ± 180.370 | 447.571 ± 369.296 | 4936.083 ± 4694.481 | 4.455 | 0.020^* |
| PLT (x103)   | Range | Mean ± SD |   |       |
|              | 134–215  | 76–200  | 61–334 | 1.100 | 0.346 |
|              | 181.333 ± 42.194 | 133.143 ± 48.746 | 129.708 ± 59.979 | 1.100 | 0.346 |
| HGB (g/dL)   | Range | Mean ± SD |   |       |
|              | 12–13.3  | 10.8–14.6 | 8.5–17.5 | 0.137 | 0.873 |
|              | 12.633 ± 0.651 | 12.443 ± 1.218 | 12.192 ± 1.806 | 0.137 | 0.873 |
| INR          | Range | Mean ± SD |   |       |
|              | 1.02–1.26 | 1.18–2.5  | 1.02–2.7  | 1.234 | 0.305 |
|              | 1.123 ± 0.123 | 1.534 ± 0.442 | 1.369 ± 0.385 | 1.234 | 0.305 |
| PT (sec)     | Range | Mean ± SD |   |       |
|              | 12.2–15  | 14.3–30  | 12.2–33  | 1.141 | 0.332 |
|              | 13.400 ± 1.442 | 18.457 ± 5.283 | 16.575 ± 4.981 | 1.141 | 0.332 |
| BMI (kg/m2)  | Range | Mean ± SD |   |       |
|              | 22.7–23.5 | 22.2–23.9  | 22.1–23.8  | 0.556 | 0.579 |
|              | 23.133 ± 0.404 | 23.029 ± 0.582 | 23.242 ± 0.456 | 0.556 | 0.579 |
| S.UREA range (ng/l) | Range | Mean ± SD |   |       |
|              | 27–30    | 26–43   | 26–40   | 1.259 | 0.298 |
|              | 29.000 ± 1.732 | 33.143 ± 5.581 | 31.458 ± 3.413 | 1.259 | 0.298 |
| Tumor size   | Range | Mean ± SD |   |       |
|              | 2.5–3   | 2.5–4.5  | 2.5–5.5  | 5.672 | 0.008^* |
|              | 2.667 ± 0.289 | 2.943 ± 0.714 | 3.917 ± 0.903 | 5.672 | 0.008^* |

*p-value<0.05 (significant)
serum ALP, serum AFP, serum creatinine, serum urea, platelets, INR, and PT. But, there were no significant differences between the three studied groups regarding hemoglobin and BMI. No significant difference was found between HCC and chronic hepatitis groups regarding studied parameters except AFP. Moreover, a significant difference between control and chronic hepatitis groups regarding all parameters except AFP, serum creatinine, and urea.

Similar results were found by Barooah et al. (2019) and Raafat Rowida et al. (2020). They reported that serum levels of ALT, AST, and bilirubin were higher among patients of HCC than those of chronic liver disease [22, 25]. Also, Bruix and Sherman (2011) showed that the serum level of ALT and AST were elevated in HCC especially the advanced cases, and the difference becomes greater as the disease progresses [26]. On the other hand, AFP levels may be normal in up to 40% of patients with HCC, particularly during the early stages (low sensitivity). Elevated AFP levels may be seen in patients with cirrhosis or exacerbations of chronic hepatitis (low specificity) [27].

Our study revealed that patients with HCC had a higher frequency of Apa-I CC genotype compared to those with chronic hepatitis C or control. These results are similar to those found by Barooah et al. (2019), Raafat Rowida et al. (2020), and Hung et al. (2014) [22, 25, 28]. Hung et al. (2014) revealed that patients carrying the corresponding Apa-I CC genotype had a higher prevalence of HCC than those with CA or AA type. They revealed that age, male gender, lower platelet count (< 15 × 10^4/μL), and Apa-1 CC genotype were independent predictors for developing HCC [28]. Barooah et al. (2019) found that the frequency of the Apa-I CC genotype and Apa I C allele of the VDR gene was significantly higher in HCC and cirrhotic patients than controls. After adjusting for other covariates (age, gender, platelet count, AST, ALT, serum albumin, and viral load), logistic regression analysis showed that the Apa-I CC genotype was independent predictor of HCC development [22]. Baur et al. showed that Apa1 CC genotype was associated with a rapid fibrosis progression in cirrhotic HCV patients [29].

Our study showed a significant relation between Apa-1 VDR genotypes and AFP levels. This result was similar to that found by Raafat Rowida et al. (2020). Similar to our findings, they found that AFP was highest in those with the CC variant and platelet count was low in both CC and CA groups. However, in our study, platelet count did not reach a significant level as detected by them. They also found that Child-Pugh class C was more frequent in the CC group [25].

Conclusions
Apa-1 polymorphism is a possible predictor and prognostic marker in HCV patients that develop HCC.
10. Niu ZS, Niu XJ, Wang WH (2016) Genetic alterations in hepatocellular carcinoma: An update. World J Gastroenterol 22:9069–9095

11. CHao H, Lee CM, Lu SN, Wang JH, Hu TH, Tung HD, Chen CH, Chen WJ, Changchien CS (2006) Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. J Viral Hepat 13:409–414

12. Köstner K, Denzer N, Müller CS, Klein R, Tilgen W, Reichrath J (2009) The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature. Anticancer Res 29(9):3511–3536

13. Kitson MT, Roberts SK (2012) D-livering the message: the importance of vitamin D status in chronic liver disease. J Hepatol 57(4):897–909. https://doi.org/10.1016/j.jhep.2012.04.033

14. Santos BR, Mascarenhas LPG, Satler F et al (2012) Vitamin D deficiency in girls with vitamin D receptor gene variants. BMC Pediatr 12:62

15. Huang YW, Liao YT, Chen W, Chen CL, Hu JT, Liu CJ, Lai MY, Chen PJ, Chen DS, Yang SS (2010) Vitamin D receptor gene polymorphisms and distinct clinical phenotypes of hepatitis B carriers in Taiwan. Genes Immun 11:87–93

16. Hoan N, Khuyen N, Giang D et al (2019) Vitamin D receptor ApaI polymorphism associated with progression of liver disease in Vietnamese patients chronically infected with hepatitis B virus. BMC Med Genet 20:201 https://doi.org/10.1186/s12881-019-0903-y

17. Li WH, Gu Z, Wang H, Nekrutenko A (2001) Evolutionary analyses of the human genome. Nature 409:847–849

18. Shasty BS (2002) SNP alleles in human disease and evolution. J Hum Genet 47:561–566

19. Bai YH, Lu H, Hong D, Lin CC, Yu Z, Chen BC (2012) Vitamin D receptor gene polymorphisms and colorectal cancer risk: a systematic meta-analysis. World J Gastroenterol 18:1672–1679

20. McClung MR, Lewiecki EM, Cohen SB (2006) Evaluation of OPN level and VDR gene polymorphism in patients with hepatocellular carcinoma postmenopausal women with low bone mineral density. N Engl J Med 354:821–831

21. Barooah P, Salkia S, Bharadwaj R et al (2019) Role of VDR, GC, and CYP2R1 polymorphisms in the development of hepatocellular carcinoma in hepatitis C virus-infected patients. Genet Test Mol Biomarkers 23(5):325–331. https://doi.org/10.1089/gtmb.2018.0170

22. Yang JD, Roberts LR (2010) Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol 7:448–458

23. Hung CH, Chiu YC, Hu TH, Chen CH, Lu SN, Huang CM, Wang JH, Lee CM (2014) Significance of vitamin D receptor gene polymorphisms for risk of hepatocellular carcinoma in chronic hepatitis C. Transl Oncol 7(4):503–507

24. Mullhaupt B, Geier A (2012) Combined effect of 25-OH vitamin D plasma levels and genetic VDR B receptor (NR 1I1 ) variants on fibrosis progression rate in HCV patients. Liver Int 32:635–643. https://doi.org/10.1111/j.1478-3231.2011.02674.x

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.